Therefore, since anakinra will block both the effects of IL-1β and IL-1α and in addition has impact on several key inflammatory mechanisms such as NLRP3 inflammasome activation and autophagy, anakinra might be beneficial in CF by targeting multiple pathogenic mechanisms. Here, IL1B is linked to cystic fibrosis.